Peer-Reviewed Results of Bangladesh Medical College Prospective Study: Ivermectin & Doxycycline Combination Effectively Treats Mild to Moderate COVID-19

Peer-Reviewed Results of Bangladesh Medical College Prospective Study Ivermectin & Doxycycline Combination Effectively Treats Mild to Moderate COVID-19

The Journal of Bangladesh College of Physicians and Surgeons accepted the first case series study authored by Dr. Tarek Alam working with the Bangladesh Medical College. TrialSite showcased these results after an interview with Dr. Alam. Titled A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline,” the peer-reviewed conclusion suggests the combination of ivermectin and doxycycline is very effective in viral clearance of mild to moderately sick COVID-19 patients. The findings from this important medical journal in Bangladesh, the world 8th most populated nation, are not trivial nor remote. Rather, they reflect a growing real-world evidence that national research agencies, including the National Institutes of Health in the United States, should undertake larger multicenter studies to validate and recommend this combination therapy to include in national COVID-19 guidelines. Called “The People’s Medicine” in Bangladesh, the time is now for formalized study in the United States.

As COVID-19 continues to wreak havoc around the world—as of this writing, 31 million reported cases worldwide with nearly 1 million deaths (200,000 in America alone)—health, economies, and civil societies feel the growing strain. Cost effective and widely available treatments must be found to economically and expeditiously address and contain this contagion. A study of ivermectin isn’t a replacement for the mission-critical vaccines (Moderna, Pfizer, etc.) and powerful monoclonal antibodies under development by Regeneron, Eli Lilly and others. Rather, they all complement another as a range of therapies at different price points are required to take on COVID-19 for the long run.

Dr. Alam and many others first observed the findings out of Monash University with great interest. Those in vitro studies found that ivermectin could reduce the concentration of SARS-CoV-2 4000 to 5000 fold.

Dr. Alam has been a pioneer world wide in establishing the potential safety and efficacy of ivermectin in combination with doxycycline for treating patients with mild to moderate COVID-19. In interviews with TrialSite, the physician was adamant that the real world data points were accumulating in favor of off label use. However, Dr. Alam advocates evidence-based medicine and has been pushing in his country for a large, randomized controlled study.

In addition to this recent peer-review published accomplishment, Dr. Alam reports to TrialSite News via email that his wait is over and that, thankfully, his larger randomized controlled study has been approved in Bangladesh by the appropriate authorities; he will commence immediately with this pivotal clinical trial.

Study Results

In this hospital approved protocol, a prospective study combining ivermectin and doxycycline for treating mild to moderately ill patients infected with SARS-CoV-2, 100 patients infected with COVID-19 were enrolled with a predefined inclusion and exclusion criteria. The study included 64 males and 36 females respectively aging from 8 to 84. After administration of the off label combination therapy, all patients tested negative and their symptoms demonstrated marked improvement within 72 hours. The study team identified no noticeable side effects.

The study team concluded in this peer-reviewed report that ivermectin and doxycycline were “found to be very effective in viral clearance in mild and moderately sick COVID-19 patients.”

Randomized Trial Moves Forward

As mentioned previously, Dr. Alam informed TrialSite that the authorities in Bangladesh have approved the randomized controlled trial based on the efforts of his work to date. TrialSite reported that Dr. Alam was first planning this study to further investigate “the People’s Medicine” back in July.  

The Journal of Bangladesh College of Physicians and Surgeons

The Journal of Bangladesh College of Physicians and Surgeons is a peer reviewed journal published four times a year (Jan, April, July and Oct). The Bangladesh College of Physicians and Surgeons has been a pioneer in developing post-graduate medical education in Bangladesh. Historically, the college bears a heritage to the College of Physicians and Surgeons of Pakistan of which it was the eastern wing. A unique institute of medical science in Bangladesh that awards Fellow of College of Physicians and Surgeons (FCPS) degrees to the medical and dental graduates

Back in 1972, the Government of the Peoples’ Republic of Bangladesh constituted an ad hoc committee of the College with Professor K S Haque as the President in 1972. All fellows of the College of Physicians and Surgeons of Pakistan who hailed from Bangladesh were admitted as the founder fellows. With great endeavors and untiring efforts, these people were able to hold the first examination in July 1972. A memorable and mighty move was the shift of the College to its own premises at Mohakhali in January 1982. The College owes this achievement to its then President Prof. MA Matin.

Bangladesh Medical College

Established in 1986, Bangladesh Medical College is the oldest private medical school in Bangladesh. Located in Dhanmondi, Dhaka, its affiliated with University of Dhaka as a constituent college.

Bangladesh and Research

Recall TrialSite News published a survey of research in Bangladesh. The 8th most populous nation, with a rapidly growing economy and highly entrepreneurial culture, establishes a potential regional clinical trials hub

Lead Research/Investigator

Tarek Alam, MD, MBBS, Bangladesh Medical College

Call to Action: Dr. Alam and team recommend that medical societies and healthcare institutions immediately plan larger multicenter studies to validate. In the meantime, based on the results and existing safety profile of ivermectin, the investigator recommends this combination therapy in national guidelines. Dr. Alam’s larger random controlled study has been approved by Bangladesh authorities, and TrialSite will update the TrialSite Network with findings as the study unfolds.


  1. Have the results of this test been forwarded to the people who could possibly get the ivermectin doxycycline and or zinc that Barody suggests approved by the FDA and World Health Organization?

  2. Epistemology, the study of the foundations of knowledge, brings us to the realization that a minimum of 99.9% what we human beings call knowledge rests on an unstable, sometimes fragile, and often multi pronged foundation.

    The randomized clinical trial (RCT), except in situations where the problem is relatively simple — you’re firing shots into a sample of recipients, some shots are hoped-for magic bullets, and no one in the sample knows who got those bullets.

    If the sample does not appropriately represent the heterogeneity of the target population relative to pertinent attributes and behaviours that have causal relevance, even in that simple situation the RCT can bring you seriously wrong findings as regards what will happen when the bullets are fired across the whole population.

    So far we have considered the simple situation — the said major bullet. What if the experiment is to consider a complex process with several chemical substances taken at different times according to a protocol, and with behavioural constraints whose satisfaction the experimenter cannot examine — e.g., a treatment protocol where there is a cocktail of drugs, and there are associated behavioural rules. In this situation the limitations of the RCT become substantial in number.

    Here’s an important t limitation that few are discussing. A good design for a complex treatment protocol is inevitably very expensive, and no party will produce the financing for that; because the payoff from the financial investment is surely to be a big loss. So, at the end of the day, those who like to complain about “lack of appropriate clinical trials” have a wide open field, with no opposition, in which to make their claims.

    The text above is a long-winded way of advocating that we pay attention to the fact that the randomized clinical trial (RCT) as a widely used process is much less than 100 years old, while medicine contains widely accepted knowledge built up of a period of more than 1000 years.

    So, if we are really serious about understanding the foundations of knowledge in medicine, we should welcome the message of the opening paragraph of this TrialSiteNews article.

    It does have a self-contradiction at a key point, however. After citing “growing real world evidence” , it later refers to “evidence-based medicine” as if that is equivalent to RCTs. It is more useful to say that RCTs are the best known way for health institutions to allocate resources they control and for issuing their particular guidelines. This is a far cry from supporting the claim that they comprise a standard to which all medical knowledge needs to aspire.

    Finding “a range of [complementary] therapies at different price points” seems appropriate for world as heterogenous as ours, and where leaders in some countries are under enormous pressure to support strategies designed to save lives “yesterday” among those that are *already infected*.

    And let us add immediacy of availability to the matter of varying price points. In some countries, the leaders do not have the luxury of being able to restrict availability for marketing reasons.

  3. Great to hear Dr. Alam’s excellent results stood up to peer review and have now garnered the investment in an RCT! The compelling and still accumulating RWE strongly supports outpatient off label use while the RCTs run their course. The days of “treating” outpatients with chicken soup, Tylenol, and finger crossing should be a thing of the past!

  4. The evidence keeps growing. This is very interesting. As far as RCT’s are concerned, Professor Brody has a very interesting take on those in situations such as the one we are in!